Project Scope

The scope of this project is to evaluate and recommend approaches for SEND harmonization to better enable analysis of historical control data. SEND harmonization strategies include creation of new variables, controlled terminology, preferred terms, reference lists and/or analysis strategies (scripts) to enable cross study analysis. Developing a solution framework for variability that includes representation of stakeholders involved in the creation and use of SEND datasets will enable more efficient routine analysis of warehoused SEND data.

Project Leads

Email

Kevin Synder (FDA)

kevin.snyder@fda.hhs.gov

Mark Carfagna (Eli Lilly,  BioCelerate Consortium)

carfagna_mark_a@lilly.com

Katie Warren (PHUSE Project Assistant)

katie@phuse.global

Objectives & DeliverablesTimelines
PHUSE Publication of White Paper: Recommendations for Consistent Representation of Test Facilities, Test Sites, and Subject Metadata Using SEND Controlled TerminologyQ2 2022

CURRENT STATUS Q3/4 2022

  • Draft white paper on vehicle project implementation  

Project Members 

Organisation 
Annika KreuchwigBayer
Bill HouserBristol Myers Squibb,  BioCelerate Consortium
Cara Rinaldi BioCelerate

Cheryl Sloan

Bristol Myers Squibb,  BioCelerate Consortium

Deepa Smant

Comcast
Frank BringezuMerck 

Gen Sato

Eisai 
Joseph Horvath Bristol Myers Squibb
Laura Kaufman Pointcross
Lokesh Babu Pointcross
Michael DeNieu Labcorp
Michael WaskoPDS Life Sciences 

Michele Dunleavy

Biocelerate
Nicolas PhilippePointCross Life Sciences 
Patricia BrundageFDA
Rick ThompsonJanssen Research & Development,  BioCelerate Consortium

Rupesk Katta

Xybion
SivaRamaKrishna VemiReddy Pointcross
Steve PolleyGSK

Sudharrshan Muthukumarasamy

Xybion
Sue DehavenSanofi
Todd PageEli Lilly
Vidhuna SadanandanLabcorp
Wang WenxianBristol Myers Squibb,  BioCelerate Consortium
William Houser Bristol Myers Squibb
  • No labels